Amgen (AMGN) Q4 2024 Earnings Call Transcript
All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the conclusion of the last speakers' prepared remarks. In order to ensure that everyone has a chance to participate,
Amgen Inc (AMGN) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions
Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, despite facing market challenges.
Pipeline Problems Mar Amgen’s Q4 Beat
Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 and the discontinuation of other programs.
Amgen Surpasses Q4 Earnings Forecasts
Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.
Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead
Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.
Q4 2024 Amgen Inc Earnings Call
My name is Julianne, and I will be your conference facilitator today for Amgen's fourth quarter and full year 2024 financial results conference call. (Operator Instructions) I would now like to introduce Justin Claeys, Vice President of Investor Relations. Mr. Claeys, you may now begin.
Amgen Inc. Q4 Profit Decreases, But Beats Estimates
Amgen Inc. (AMGN) reported a profit for fourth quarter that decreased from the same period last year but beat the Street estimates.
Amgen Earnings Report: Q4 Overview
Amgen AMGN announced its Q4 earnings on Tuesday, February 4, 2025 at 04:01 PM. Here's a breakdown of the earnings report. Amgen beat estimated earnings by 5.0%, reporting an EPS of $5.31 versus an estimate of $5.08. Revenue was up $890.00 million from the same period last year.
Amgen Set to Report Q4 Earnings: Is a Beat in the Cards?
Volume growth of AMGN's key drugs like Prolia, Repatha and Evenity is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics
Amgen (AMGN) reported $9.09 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 10.9%. EPS of $5.31 for the same period compares to $4.71 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $8.
Amgen Q4 Earnings Preview: Street expects revenue to rise more than 8%
Biopharmaceutical company Amgen (AMGN) is set to announce its fourth quarter earnings results on Tuesday, February 4th, after ...
precisionmedicineonline2h
Amgen Reports More Than $2B in Oncology Revenues in Q4
Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.
Amgen price target raised to $328 from $322 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen (AMGN) to $328 from $322 and keeps an Equal Weight rating on the ...
Alphabet: Q4 Earnings Snapshot
The average estimate of 17 analysts surveyed by Zacks Investment Research was for earnings of $2.12 per share. The internet search leader posted revenue of $96.47 billion in the period. After ...